- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02207699
Evaluation of the Effect of Benzonatate on QT Intervals Following Single Dose Administration of Benzonatate to Healthy Volunteers
July 31, 2014 updated by: Pfizer
The primary objective of this study is to determine the effects of benzonatate (200 mg and 800 mg) on the QT interval following single dose oral administration at each time point post-dose.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
68
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kansas
-
Overland Park, Kansas, United States, 66212
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 53 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy male and female subjects between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12- lead ECG and clinical laboratory tests.
Female subjects of non-childbearing potential must meet at least one of the following criteria:
- Achieved postmenopausal status, defined as: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and have a serum FSH level within the laboratory's reference range for postmenopausal females;
- Have undergone a documented hysterectomy and/or bilateral oophorectomy;
- Have medically confirmed ovarian failure. All other female subjects (including females with tubal ligations and females that do NOT have a documented hysterectomy, bilateral oophorectomy and/or ovarian failure) will be considered to be of childbearing potential.
- Body mass index (BMI) of 17.5 to 30.5 kg/m2, inclusive, and a total body weight >50 kg (110 lb).
- Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all aspects of the study.
- Subjects willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
Exclusion Criteria:
- Significant ECG abnormality at screening as determined by the investigator.
- History or risk factors of QT prolongation or torsades de pointes, congenital deafness and family history of sudden death.
- 12-lead ECG demonstrating QTcF >450 msec or a QRS interval >110 msec at Screening.
- Use of medications or dietary supplements capable of inducing or inhibiting hepatic enzyme metabolism or transport (e.g., barbiturates, rifampin, carbamazepine, phenytoin, primidone, or St. John's Wort) within 28 days of the first dose of study medication.
- Consumption of grapefruit or grapefruit containing products within 7 days prior to the first dose of study medication.
- Known history of hypersensitivity, allergy, severe adverse drug reaction or intolerance to quinolone antibiotics.
- Known hypersensitivity to benzonatate or other ester-type local anesthetics (ie, tetracaine, procaine).
- Subjects with a presence or history of dysphagia or difficulty swallowing pills.
- Subjects taking any concomitant anticonvulsant medications or with a history of seizure disorder.
- Subjects with a positive response to the question of actual attempt in the suicidal behavior section of the C-SSRS (Columbia-Suicide Severity Rating Scale). Subjects with active suicidal ideation with intent to act within 6 months of screening as determined by a positive response to questions 4 or 5 in the suicidal ideation section of the C-SSRS.
- Screening laboratory values considered clinically significant by the investigator.
- Screening supine blood pressure ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of rest.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
8 placebo perles given by mouth once
|
Experimental: Benzonatate 200 mg
|
2 benzonatate 100 mg perles and 6 placebo perles give by mouth once
|
Experimental: Benzonatate 800 mg
|
8 benzonatate 100 mg perles given by mouth once
|
Active Comparator: Moxifloxacin 400 mg
|
1 moxifloxacin 400 mg tablet given by mouth once
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Fridericia-corrected QTc change from the pre-dose time point to the post-dose time points following administration of study drug in therapeutic (200 mg) and supratherapeutic doses (800 mg).
Time Frame: -1, -0.75, -0.5, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, and 24 hours
|
-1, -0.75, -0.5, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, and 24 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
QT interval for Benzonatate, 4-(butylamino)benzoic acid (BBA-major metabolite of benzonatate), and moxifloxacin.
Time Frame: -1, -0.75, -0.5, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, and 24 hours
|
-1, -0.75, -0.5, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, and 24 hours
|
PR interval, QRS complex from single 12-lead electrocardiogram (ECG)
Time Frame: Screening, Day 0, and Day 1 at 4, 8, and 24 hours after dosing
|
Screening, Day 0, and Day 1 at 4, 8, and 24 hours after dosing
|
Cmax (maximum plasma concentration) for BT and BBA measured in mcg/mL
Time Frame: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 12 hours
|
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 12 hours
|
Tmax (time of maximum plasma concentration) for BT and BBA measured in minutes
Time Frame: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 12 hours
|
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 12 hours
|
t½ (terminal half-life) for BT and BBA measured in minutes
Time Frame: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 12 hours
|
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 12 hours
|
AUClast for BT and BBA measured in mcg•hr/mL
Time Frame: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 12 hours
|
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 12 hours
|
AUCinf for BT and BBA measured in mcg•hr/mL
Time Frame: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 12 hours
|
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 12 hours
|
Cmax(dn) for BT and BBA measured in mcg/mL
Time Frame: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 12 hours
|
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 12 hours
|
AUClast(dn) for BT and BBA measured in mcg•hr/mL
Time Frame: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 12 hours
|
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 12 hours
|
AUCinf(dn) for BT and BBA measured in mcg•hr/mL
Time Frame: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 12 hours
|
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 12 hours
|
CL/F for BT measured in L/hr
Time Frame: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 12 hours
|
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 12 hours
|
Vz/F for BT measured in L
Time Frame: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 12 hours
|
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 12 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2014
Primary Completion (Actual)
July 1, 2014
Study Completion (Actual)
July 1, 2014
Study Registration Dates
First Submitted
June 16, 2014
First Submitted That Met QC Criteria
July 31, 2014
First Posted (Estimate)
August 4, 2014
Study Record Updates
Last Update Posted (Estimate)
August 4, 2014
Last Update Submitted That Met QC Criteria
July 31, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B3551003
- BT-10-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Benzonatate 200 mg
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Unknown
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Unknown
-
Yuhan CorporationCompleted
-
Novartis PharmaceuticalsRecruitingNon-Small Cell Lung CarcinomaIndia
-
Mylan Pharmaceuticals IncCompletedHealthyUnited States
-
Atabay Kimya Sanayi Ticaret A.S.Novagenix Bioanalytical Drug R&D Center; Farmagen Ar-Ge Biyot. Ltd. StiCompleted
-
Novelfarma Ilaç San. ve Tic. Ltd. Sti.Novagenix Bioanalytical Drug R&D Center; Farmagen Ar-Ge Biyot. Ltd. StiCompleted
-
Gannex Pharma Co., Ltd.Ascletis Pharmaceuticals Co., Ltd.RecruitingAdvanced Solid TumorsUnited States